Lurasidone in Therapy of Treatment-resistant Ultra-rapid Cycling Bipolar Disorder: Case Report
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Lurasidone is an atypical antipsychotic approved for the treatment of schizophrenia and bipolar depression. It seems to have a favorable metabolic profile and low risk of causing adverse interactions. Here we present a case of a 25-year old female patient with treatment-resistant ultra-rapid cycling bipolar disorder, obesity, hypothyroidism, and epilepsy. Because of predominant depressive symptoms, occasional occurrence of brief psychotic symptoms and patient’s somatic comorbidities, treatment with lurasidone was initiated. Clinical improvement was observed 3 weeks and cessation of ultra-rapid cycling course of the disease 8 weeks after the beginning of lurasidone treatment. The patient’s level of functioning improved and body mass significantly decreased, with good tolerance of the pharmacotherapy. Lurasidone seems to be a promising treatment option in patients with treatment-resistant rapid cycling bipolar disorder.
Abstract
Lurasidone is an atypical antipsychotic approved for the treatment of schizophrenia and bipolar depression. It seems to have a favorable metabolic profile and low risk of causing adverse interactions. Here we present a case of a 25-year old female patient with treatment-resistant ultra-rapid cycling bipolar disorder, obesity, hypothyroidism, and epilepsy. Because of predominant depressive symptoms, occasional occurrence of brief psychotic symptoms and patient’s somatic comorbidities, treatment with lurasidone was initiated. Clinical improvement was observed 3 weeks and cessation of ultra-rapid cycling course of the disease 8 weeks after the beginning of lurasidone treatment. The patient’s level of functioning improved and body mass significantly decreased, with good tolerance of the pharmacotherapy. Lurasidone seems to be a promising treatment option in patients with treatment-resistant rapid cycling bipolar disorder.
참고문헌 (23)
- Loebel A, "Lurasidone : a novel antipsychotic agent for the treatment of schizophrenia and bipolar depression", BJPsych Bull, 39, pp.237~241 (2015)
- Ishibashi T, "Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7(5-HT7)and 5-HT1A receptor activity", J Pharmacol Exp Ther, 334, pp.171~181 (2010)
- Citrome L, "Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed", J Affect Disord, 155, pp.20~27 (2014)
- Loebel A, "Lurasidone monotherapy in the treatment of bipolar I depression : a randomized, double-blind, placebo-controlled study", Am J Psychiatry, 171, pp.160~168 (2014)
- Leucht S, "Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia : a multiple-treatments meta-analysis", Lancet, 382, pp.951~962 (2013)
- American Psychiatric Association, "Diagnostic and statistical manual of mental disorders" (2013), American Psychiatric Association
- Carvalho AF, "Rapid cycling in bipolar disorder : a systematic review", J Clin Psychiatry, 75, pp.e578~ (2014)
- Gigante AD, "Psychiatric and clinical correlates of rapid cycling bipolar disorder : a cross-sectional study", Braz J Psychiatry, 38, pp.270~274 (2016)
- Hajek T, "Rapid cycling bipolar disorders in primary and tertiary care treated patients", Bipolar Disord, 10, pp.495~502 (2008)
- Lee S, "Rapid-cycling bipolar disorder : cross-national community study", Br J Psychiatry, 196, pp.217~225 (2010)
- Valentí M, "Risk factors for rapid cycling in bipolar disorder", Bipolar Disord, 17, pp.549~559 (2015)
- Fountoulakis KN, "The treatment of bipolar disorder: integrative clinical strategies and future directions", pp.65~80 (2017), Oxford University Press
- Fountoulakis KN, "A systematic review of the evidence on the treatment of rapid cycling bipolar disorder", Bipolar Disord, 15, pp.115~137 (2013)
- Yatham LN, "Canadian Network for Mood and Anxiety Treatments(CANMAT)and International Society for Bipolar Disorders(ISBD)2018 guidelines for the management of patients with bipolar disorder", Bipolar Disord, 20, pp.97~170 (2018)
- Bazire S, "Psychotropic drug directory 2018: the professionals’pocket handbook and aide memoire", pp.59~60 (2018), Lloyd-Reinhold Publications
- Ketter TA, "Lurasidone in the long-term treatment of patients with bipolar disorder : a 24-week open-label extension study", Depress Anxiety, 33, pp.424~434 (2016)
- McIntyre RS, "Lurasidone in the treatment of bipolar depression with mixed(subsyndromal hypomanic)features : post hoc analysis of a randomized placebo-controlled trial", J Clin Psychiatry, 76, pp.398~405 (2015)
- Calabrese JR, "Lurasidone in combination with lithium or valproate for the maintenance treatment of bipolar I disorder", Eur Neuropsychopharmacol, 27, pp.865~876 (2017)
- Wichniak A, "Metabolic risk reduction in patients with schizophrenia treated with antipsychotics : recommendations of the Polish Psychiatric Association", Psychiatr Pol, 53, pp.1191~1218 (2019)
- Gavin P Reynolds, "Adjunctive Lurasidone Suppresses Food Intake and Weight Gain Associated with Olanzapine Administration in Rats", Clinical Psychopharmacology and Neuroscience, 17(2), pp.314~317 (2019), 대한정신약물학회[DOI]
- Huhn M, "Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia : a systematic review and network meta-analysis", Lancet, 394, pp.939~951 (2019)
- Meyer JM, "Weight changes before and after lurasidone treatment : a realworld analysis using electronic health records", Ann Gen Psychiatry, 16, pp.36~ (2017)
- Bazire S, "Psychotropic drug directory 2018: the professionals’pocket handbook and aide memoire", pp.255~256 (2018), Lloyd-Reinhold Publications